Lung cancer – Part 4 – Multi-Disciplinary Team
When people are first diagnosed with lung cancer they’re often involved with a team of health care professionals. Find out who is involved and how the various roles work together.
JVZoo Product Feed
Dr. Yung Discusses Forming a Multidisciplinary Team
Rex Chin-Wei Yung, MD, Assistant Professor of Medicine, Assistant Professor of Oncology, The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, discusses the challenges that forming a multidisciplinary team can create, particularly the introduction of the pulmonologist for treating lung cancer. The inclusion of any new person into a group can be disruptive. There needs to be a clear reason why the new individual is an asset to the team. This needs to be clear both to the existing group and the person being added. Time is the most valuable asset and it is important that no one feels as if his or her time is being wasted. The pulmonologist in a multimodality group needs to know they are providing a useful service to the patient. Establishing a routine and constant flow of patients can help the pulmonologist gain interest as a member. In many groups there is a zero-sum gain feeling. If a surgeon recommends a procedure to a pulmonologist he may feel that he is missing out on an opportunity but this is not the case. In multimodality therapy there is a higher chance an issue will be detected and treated, which can result in more surgery. The end result is better treatment; surgery can be given or prevented more accurately. The primary focus should be on the welfare of the patient.
Video Rating: 0 / 5
JVZoo Product Feed
Arabic Part 4 – Multi-disciplinary Team – Living with Lung Cancer
Video Rating: 0 / 5
JVZoo Product Feed
Mesothelioma – European Multidisciplinary Cancer Congress 2011
Interview with Fortunato Ciardiello, MD, PhD about the use of Vorinostat in patients with advanced pleural mesothelioma (VANTAGE 014): urgent need to identify new drugs to face peak of cases in 10 years. Interview by the European Society for Medical Oncology (ESMO).
JVZoo Product Feed
Categories: Videos Tags: congress, mesothelioma, cancer, european, multidisciplinary, 2011
2010 Portland BetterBricks Awards – Multi-Disciplinary Team
From the start of the project, the Slocum Center was more than just a healthcare building—it needed to promote the health of the community and the environment. The Slocum Center partnered with McKay Investment Company to transform a three-plus acre site from a wasteland of asphalt, asbestos and a buried gas tank into a landmark statement for wellness and environmental stewardship. The Neenan Company, design-builder on the project, Solarc Architecture + Engineering, the MEP engineer and LEED consultant, provided the technical expertise to help bring this vision to a reality. The result was the Slocum Center for Orthopedics and Sports Medicine—a LEED Gold Certified building. It is one of only three buildings in Eugene and the only healthcare facility in the community to receive a LEED Gold Certification. The Slocum Center was created through strong integration and cooperation. Designing a building to LEED standards in a healthcare facility presents specific challenges not present in other building types, including maintaining patient privacy, safety and infection control. Healthcare buildings are also some of the most energy intensive buildings around. This team managed to accomplish it all while creating a building that saves 37 percent per square foot per year.
Video Rating: 5 / 5
JVZoo Product Feed
Categories: Videos Tags: betterbricks, portland, awards, multidisciplinary, team, 2010
Role of CT Surgery in Multi-Disciplinary Management of Non-Small Cell Lung Cancer
Role of Cardio-thoracic Surgery in Multi-Disciplinary Management of Non-Small Cell Lung Cancer – Slideshow presentation by Divyakant B. Gandhi, MD FACS FRCS, Clinical Asst. Professor, Michigan State University
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: role, multidisciplinary, management, surgery, lung, nonsmall, cancer, cell
FMH’s Multidisciplinary Approach to Lung Cancer Treatment
Thoracic Surgeon Paul Chomiak shows us how lung cancer patients are guided through the process from diagnosis to treatment — quickly — at Frederick Memorial Healthcare System’s Regional Cancer Therapy Center. Also featured: Dr. Brian O’Connor and Dr. KC Lee
Video Rating: 1 / 5
JVZoo Product Feed
Categories: Videos Tags: lung, part, macedonian, living, multidisciplinary, team, cancer
Part 1- Multidisciplinary Clinics at the James Graham Brown Cancer Center Lung Cancer
Tune into WAVE-3 on Jan. 12th, from 10:00A – 11:00A as the Listens program features to of our Multidisciplinary Clinics from the James Graham Brown Cancer Center. Thoracic Surgeon, Michael Bousamra, MD, and Medical Oncologist Goetz Kloecker, MD, will represent the Lung Clinic. They will discuss the latest treatments and take be taking calls from viewers. This is part of a regularly monthly feature of UofL Physicians on WAVE-3 Listens, hosted by Cindi Sullivan.
An innovative clinical trial uses tumor biopsy information and unique statistical method to match four drugs to potential biomarkers that might guide treatment. Study leader Dr. Edward Kim of The University of Texas MD Anderson Cancer Center discusses BATTLE results.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: multidisciplinary, clinics, graham, part, lung, center, james, brown, cancer
Multidisciplinary Lung Nodule Clinic at Aurora BayCare Medical Center
Dr. Dhimant R. Patel is an oncologist at Aurora BayCare and specializes in lung cancer. He explains what the hospital’s Multidisciplinary Lung Nodule Clinic is, by starting with an answer to the most basic question: “What is considered a ‘nodule?’ In December, the Multidisciplinary Lung Nodule Clinic at Aurora BayCare will offer CT and PET imaging options using a 128-slice CT scanner, which provides some of the fastest and highest resolution imaging available. Also in January 2012, Aurora BayCare will become home to northeast Wisconsin’s only TrueBeam™ treatment system, developed to treat tumors quickly and precisely. TrueBeam, by Varian Medical Systems, synchronizes imaging, a patient’s positioning, motion management and the delivery of treatment to more accurately target tumors that move as a patient breathes. The Multidisciplinary Lung Nodule Clinic at Aurora BayCare Medical Center provides evidence-based testing and monitoring for persons with pulmonary nodules. The clinic team reviews a person’s health history and works with the patient and referring physician to quickly diagnose the nodule, provide a personalized monitoring or treatment plan, and guide the patient throughout the entire process. The team includes a pulmonologist (respiratory doctor), radiologist, thoracic (chest) surgeon and nurse navigator. The nurse navigator assists each patient through diagnosis, treatment and follow-up care. Referrals to Aurora BayCare Medical Center’s Multidisciplinary Lung …
JVZoo Product Feed
Lung Cancer is Treated with a Multi-Disciplinary Approach at Henrico Doctors’ Hospital; Dr. Buckman
Lung Cancer is Treated with a Multi-Disciplinary Approach at Henrico Doctors’ Hospital. Dr. Peter Buckman explains the approach taken by the hospital and how it benefits patients suffering from lung cancer. henricodoctors.com
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: multidisciplinary, doctors, henrico, treated, lung, cancer, hospital., approach, buckman
New Pulmonary Vascular Disease Program Provides Highly Specialized, Multidisciplinary Care
New Pulmonary Vascular Disease Program Provides Highly Specialized, Multidisciplinary Care
Article by Suzanne Benz
Specialists in the new Pulmonary Vascular Disease Program, directed by pulmonologists Aaron B. Waxman, MD, PhD, and Barbara A. Cockrill, MD, provide highly-specialized, multidisciplinary evaluation and care for patients with complex pulmonary vascular conditions, including unexplained dyspnea, pulmonary arterial hypertension (PAH), and pulmonary hypertension (PH) associated with heart disease, COPD, chronic thromboembolic disease, liver disease, and other conditions.
Pulmonologists in the Program work closely with cardiologists and other cardiovascular specialists in the Brigham and Women’s Hospital Carl J. and Ruth Shapiro Cardiovascular Center and the Boston Adult Congenital Heart Service (BACH), a joint service of Brigham and Women’s Hospital and Children’s Hospital Boston led by Michael J. Landzberg, MD.
Dr. Waxman and Dr. Cockrill are offering a broad range of active clinical trials evaluating new treatment strategies for pulmonary hypertension (PH), including new oral drugs that may serve as alternatives to intravenous medications, as well as expanded indications for three existing FDA-approved classes of drugs for PH. Current trials include:
*ARTEMIS-PH — A Phase III study evaluating the efficacy and safety of Ambrisentan, a phosphodiesterase type-5 inhibitor (PDE-5i), will compare the change in six-minute walk distance after initiating Ambrisentan or placebo treatment in subjects with pulmonary hypertension (PH) associated with ideopathic pulmonary fibrosis (IPF). Men and women 40 to 80 years-of-age with a diagnosis of IPF based on ATS-ERA guidelines and PH based on right heart catheterization may be eligible for this trial;
*ATHENA-1 — A Phase IV, open-label study designed to evaluate the change from baseline in pulmonary vascular resistance (PVR) and other hemodynamic parameters following the addition of Ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects with pulmonary arterial hypertension (PAH) who have demonstrated a sub-optimal response to a PDE-5i. Patients with a diagnosis of PAH who have been treated with PDE-5i therapy for at least 12 weeks and demonstrated a sub-optimal response may be eligible for this trial;
*PATENT-1 — A Phase III, randomized, placebocontrolled study to assess the efficacy and safety of oral BAY 63-2521 in treatment of nave patients and patients being treated with an ERA or prostacyclin analogue with symptomatic PAH. Patients with a diagnosis of PAH who have been naïve to treatment or have been treated with ERA or prostacyclin analogue for at least 90 days may be eligible for this trial. Patients enrolled in the PATENT-1 study will be eligible to enroll in PATENT-2, an open-label, long-term extension study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic PAH;
*Oral Prostacyclin — A Phase III, international, randomized, placebo-controlled study to compare the efficacy and safety of oral UT-15C SR and assess the effect of UT-15C SR on exercise capacity compared to placebo in subjects with PAH. Adult men or women with a diagnosis of PAH by right heart catheterization who have been naïve to PAH treatment may be eligible for this trial. Another exercise capacity study with UT-15C SR tablets is available for PAH subjects who have been treated with ERA and/or PDE-5i for at least 90 days. Patients enrolled in either of these studies will be eligible for an open-label extension trial of UT-15C SR in subjects with PAH.
For more information regarding these trials, as well as other clinical trials available through the Pulmonary Vascular Disease Program, please contact Laurie Lawler, RN, at (617) 525-9731 or llawler@partners.org.
Indications for Referral The Pulmonary Vascular Disease Program provides individualized evaluation and treatment for patients with:
* Unexplained dyspnea;
* Pulmonary arterial hypertension (PAH);
* Pulmonary hypertension (PH) associated with heart disease, COPD, chronic thromboembolic disease, liver disease, and other conditions.
Information and Referrals For more information, or to refer a patient, please contact our Referral Coordinators at (617) 732-9894 or email bwhteleservices@partners.org.
About the Author
Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, is consistently ranked as one of the nation’s leading hospitals. With a state-of-the-art cardiovascular center & orthopedic center of excellence, BWH is committed to excellence in patient care with expertise specialty of medicine and surgery.
Dyane describes how testing and treatments at a pulmonary fibrosis foundation Center of Excellence has proved beneficial. For more information on Pulmonary Fibrosis visit www.empowher.com
JVZoo Product Feed
Categories: Articles Tags: specialized, multidisciplinary, program, vascular, pulmonary, highly, provides, care , disease
Part 3 – Multidisciplinary Clinics at the James Graham Brown Cancer Center Lung Caner
Tune into WAVE-3 on Jan. 12th, from 10:00A – 11:00A as the Listens program features to of our Multidisciplinary Clinics from the James Graham Brown Cancer Center. Thoracic Surgeon, Michael Bousamra, MD, and Medical Oncologist Goetz Kloecker, MD, will represent the Lung Clinic. They will discuss the latest treatments and take be taking calls from viewers. This is part of a regularly monthly feature of UofL Physicians on WAVE-3 Listens, hosted by Cindi Sullivan.
Video Rating: 0 / 5
This lady was suffering from womb,bowel,lung and liver cancer and she was suffering so much without enabling her to get up from the bed even.One month homeopathy has cured her 80% giving her stamina relieving her from all aches and pains while giving her skin a rosy healthy hue too. for further details- www.jeevanihw.com and www.jeevanihasantha.com.
JVZoo Product Feed
Categories: Videos Tags: multidisciplinary, part, clinics, lung, graham, caner, center, james, brown, cancer
Part 2 – Multidisciplinary Clinics at the James Graham Brown Cancer Center Lung Caner
Tune into WAVE-3 on Jan. 12th, from 10:00A – 11:00A as the Listens program features to of our Multidisciplinary Clinics from the James Graham Brown Cancer Center. Thoracic Surgeon, Michael Bousamra, MD, and Medical Oncologist Goetz Kloecker, MD, will represent the Lung Clinic. They will discuss the latest treatments and take be taking calls from viewers. This is part of a regularly monthly feature of UofL Physicians on WAVE-3 Listens, hosted by Cindi Sullivan.
JVZoo Product Feed
Categories: Videos Tags: multidisciplinary, part, clinics, lung, graham, caner, center, james, brown, cancer
Peritoneal Carcinomatosis: A Multidisciplinary Approach (Cancer Treatment and Research)
Peritoneal Carcinomatosis: A Multidisciplinary Approach (Cancer Treatment and Research)
Recent developments in regional and systemic anticancer therapies have improved the grim outlook of patients with peritoneal carcinomatosis (PC) from ovarian or gastrointestinal origin, leading to a renewed interest in both the underlying mechanisms at the origin of PC and the various therapeutic options. This is the first volume to provide a multidisciplinary approach to peritoneal carcinomatosis encompassing molecular mechanisms, histopathology, regional and systemic cytotoxic therapy, and su
List Price: $ 99.00
Price: $ 79.20
Peritoneal Carcinomatosis from Ovarian Cancer (Horizons in Cancer Research Series)
Ovarian cancer is the most common cause of death among all gynecological neoplasms. Ovarian epithelial cancer represents approximately 90 per cent of all ovarian malignant tumours. The most usual pattern of spread and probably the earliest kind of metastasis of ovarian cancer is intraperitoneal spread, caused by apoptosis of viable cancer cells, even in cases where the ovarian surface has no visible rupture. Approximately 70 per cent to 75 per cent of all ovarian cancers are being diagnosed with
List Price: $ 210.00
Price: $ 133.06
[wprebay kw="peritoneal+cancer" num="0" ebcat="-1"] [wprebay kw="peritoneal+cancer" num="1" ebcat="-1"]
Related Peritoneal Cancer Products
JVZoo Product Feed
Categories: Products Tags: research, multidisciplinary, carcinomatosis as cause of death, treatment, carcinomatosis, peritoneal, approach, cancer
